Abstract: A method of preparing a fine oil-in-water emulsion comprising an oil phase based on silicone and/or hydrocarbon oils, in which the oil phase particles have an average particle size of 150 nm or less. The emulsion is stabilized by a carboxy-modified silicone in combination with a C16 to 22 higher alcohol; a nonionic surfactant having a POE chain and an HLB of 5 to 10; and a dihydric glycol. The emulsions can be prepared without the use of a high-pressure emulsifying apparatus.

Abstract: To provide a makeup-protecting material that has an excellent color migration prevention effect, causes no color bleeding over time, gives no coating film appearing whitish, and gives no squeaky or burdensome feeling. A makeup-protecting material comprises (A) 80 to 95% by mass of trifluoropropylcyclopolysiloxane, (B) a fluorine compound-treated silica, and (C) 2 to 8% by mass of a partially crosslinked, fluorine-modified organopolysiloxane polymer.

Abstract: A controlled-release material sensitive and response to fouling organisms for an antifouling agent includes an encapsulating precursor and a crosslinking agent. A hyaluronic acid/polyL-lysine nano-shell controlled-release material is prepared by an alternating layer-by-layer self-assembly of hyaluronic acid and poly-L-lysine, and a polypropylene ammonium chloride/poly-L-glycine nano-shell controlled-release material is prepared by an alternating layer-by-layer sell-assembly of polypropylene ammonium chloride and poly-L-glycine. The crosslinking agent is composed of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxythiosuccinimide. Based on the specific catalytic hydrolysis characteristic of fouling organism extracellular proteases on the controlled-release material, the purpose of adjusting the release of antifouling agents adaptively with the change of fouling organisms in off-season/peak-season can be achieved, prolonging the service life of the antifouling coatings.

Abstract: There is provided a nanocomplex having a core-shell structure. The shell of the nanocomplex comprises a functionalized hyaluronic acid while the core of the nanocomplex comprises a flavonoid encapsulating a metal-containing compound. Preferably, the flavonoid is epigallocatechin gallate (EGCG) and the hyaluronic acid is thiol-functionalized and subsequently conjugated to the flavonoid. There is also provided a method of forming the nanocomplex, a pharmaceutical composition comprising the nanocomplex, medical uses of the nanocomplex and a method of treating a patient, preferably with cancer using the nanocomplex.

Abstract: A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.

Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

Abstract: The present invention relates to compositions, devices and methods of delayed and sustained release of energy molecules for brain function. The composition comprises an energy molecule required for human brain function; wherein the release of the energy molecule is delayed and then sustained over a period of time. The methods comprise administering the composition subject in need thereof immediately prior to going to sleep. The present invention also relates to systems for brain stimulation during sleep and methods of use thereof. The system comprises a brain stimulation module and at least one of a brain energy source, a hypnotic source, or both. The methods involve administering to a subject a brain energy molecule, a hypnotic, or both and providing to the subject during restorative sleep a sensory stimulation.

Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally aministering the compositions, such as intranasally or intravaginally.

Abstract: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.

Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.

Abstract: The present invention discloses a synergistic composition comprising 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids for use as a skin lightening agent. The invention also discloses a method of inhibiting melanin biosynthesis and tyrosinase activity in mammalian skin cells using a composition comprising 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids.

Abstract: Compositions and methods for the treatment of respiratory syncytial virus infections are provided.

Abstract: Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C.

Abstract: Disclosed herein is a personal care conditioning and/or styling composition for keratin substrate comprising: (A) at least one conditioning and/or styling copolymer obtained from polymerizing: (i) about 0.1 wt. % to 99.9 wt. % of at least one cationic or pseudo-cationic monomer selected from the group consisting of acrylamidopropyl trimethylammonium chloride (APT AC) and/or diallyl dimethyl ammonium chloride (DADMAC); and (ii) about 0.1 wt. % to 99.9 wt. % of at least one monomer comprising at least one functionalized or unfunctionalized acryloyl moiety and at least one lactam moiety; (B) at least one cosmetically acceptable excipient; and (C) optionally, at least one effective amount of personal care active ingredient. Also disclose is a process for preparing such composition and method of use thereof.

Abstract: The invention relates to a new composition in the form of a translucent, advantageously transparent, gel, without triethanolamine, comprising at least a fatty body in the form of an oleic acid an aqueous phase; and a base or a mixture of bases. The invention also relates to compositions, advantageously cosmetic compositions, comprising said gel base, such as a shaving gel. The invention also relates to a method for preparing said gel base, a shaving method, the use of said gel base and a shaving kit.

Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.

Abstract: Subject of the invention is a composition comprising: (a) at least one film-forming polymer, which does not comprise silicon, (b) at least one organic UV filter, and (c) at least one organic solvent, wherein the composition is liquid at 20° C., wherein components (a) and (b) are dissolved in solvent (c), and wherein the ratio of the total amounts of organic UV filters (b) to film-forming polymers (a) is below 6.5. The invention also relates to compositions for therapy, uses of the composition, devices and methods.

Abstract: Provided herein are microcapsules as core-shell-particles, including a polymeric shell, a method of making them, a dispersion of the microcapsules in a liquid medium and a method of using thereof. The microcapsules include a core that contains a hydrophilic component.

Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.